0.83
-0.0449 (-5.13%)
-0.0449 (-5.13%)
Upgrade to Real-Time
Market Closed
Volume | 1,626,140 |
|
|||||
News | - | ||||||
Day High | 0.877 | Low High |
|||||
Day Low | 0.825 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.8545 | 0.825 | 0.877 | 0.83 | 0.8749 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
650 | 1,626,140 | $ 0.83919 | $ 1,364,640 | - | 0.2311 - 2.54 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:02:17 | formt | 1,000 | $ 0.83 | USD |
CytoDyn Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 672.31M | 810.01M | 453.49M | $ - | $ - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
50.35M | $ - | - | - | - |
CytoDyn (QB) News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.25 | 1.27 | 0.73 | 0.9233183 | 4,303,066 | -0.42 | -33.6% |
1 Month | 0.401 | 1.30 | 0.401 | 0.834038 | 4,776,091 | 0.429 | 106.98% |
3 Months | 0.325 | 1.30 | 0.28205 | 0.6719397 | 2,678,028 | 0.505 | 155.38% |
6 Months | 0.571 | 1.30 | 0.2311 | 0.5269275 | 2,483,295 | 0.259 | 45.36% |
1 Year | 1.39 | 2.54 | 0.2311 | 0.8491443 | 2,638,304 | -0.56 | -40.29% |
3 Years | 0.44575 | 10.01 | 0.2311 | 2.73 | 3,664,953 | 0.38425 | 86.2% |
5 Years | 0.69 | 10.01 | 0.0552 | 2.62 | 2,329,231 | 0.14 | 20.29% |
CytoDyn (QB) Description
CytoDyn Inc. is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of Human Immunodeficiency Virus (HIV), Cancer, and Immunology. |